Stoke Therapeutics, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $184.4 | $36.6 | $8.8 | $12.4 | — |
| Operating income | -$20.6 | -$101.4 | -$114.8 | -$104.4 | -$86.1 |
| Net income | -$6.9 | -$89.0 | -$104.7 | -$101.1 | -$85.8 |
| Cash Flow Statement | |||||
| Free cash flow | $44.9 | -$87.1 | -$82.7 | -$35.8 | -$68.1 |
Shares outstanding 64.5M · Free float 87.6%
Annual filing data through FY ended December 31, 2025; float as of October 1, 2026.